Atorvastatin Lipid loWering Assessment surveY in patientS with hypercholesterolemia (ALWAYS), final report: Investigation according to "Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2012"

Tamio Teramoto

Atorvastatin Lipid loWering Assessment surveY in patientS with hypercholesterolemia (ALWAYS), final report: Investigation according to "Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2012"

Tamio Teramoto

臨床研究センター

研究成果: ジャーナルへの寄稿 › 記事 › 査読

4 被引用数 (Scopus)

本文言語	英語
ページ（範囲）	455-483
ページ数	29
ジャーナル	Therapeutic Research
巻	34
号	4
出版ステータス	出版済み - 2013

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

SDG 3 すべての人に健康と福祉を

他のファイルとリンク

Scopusの出版物のリンク

引用スタイル

@article{2c703687695f4045b80a74ed3f04c192,

title = "Atorvastatin Lipid loWering Assessment surveY in patientS with hypercholesterolemia (ALWAYS), final report: Investigation according to {"}Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2012{"}",

author = "Tamio Teramoto",

year = "2013",

language = "英語",

volume = "34",

pages = "455--483",

journal = "Therapeutic Research",

issn = "0289-8020",

publisher = "Life Science Publishing Co. Ltd",

number = "4",

}

Atorvastatin Lipid loWering Assessment surveY in patientS with hypercholesterolemia (ALWAYS), final report: Investigation according to "Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2012". / Teramoto, Tamio.
In: Therapeutic Research, Vol. 34, No. 4, 2013, p. 455-483.

研究成果: ジャーナルへの寄稿 › 記事 › 査読

TY - JOUR

T1 - Atorvastatin Lipid loWering Assessment surveY in patientS with hypercholesterolemia (ALWAYS), final report

T2 - Investigation according to "Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2012"

AU - Teramoto, Tamio

PY - 2013

Y1 - 2013

UR - https://www.scopus.com/pages/publications/84878028005

M3 - 記事

AN - SCOPUS:84878028005

SN - 0289-8020

VL - 34

SP - 455

EP - 483

JO - Therapeutic Research

JF - Therapeutic Research

IS - 4

ER -